# Ameparomo Capsules 250 mg Drug Use Investigation

> **NCT02680665** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 120 (actual)

## Conditions studied

- Intestinal Amebiasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02680665
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-19
- **Primary completion:** 2018-12-21
- **Final completion:** 2018-12-21
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02680665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02680665, "Ameparomo Capsules 250 mg Drug Use Investigation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02680665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*